Serotonergic Mechanisms Responsible for Levodopa-induced Dyskinesias in Parkinson's Disease Patients

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2014 Feb 18

PMID 24531549

Citations 86

Authors

Marios Politis

Kit Wu

Clare Loane

David J Brooks

Lorenzo Kiferle

Federico E Turkheimer

Peter Bain

Sophie Molloy

Paola Piccini

Affiliations

Soon will be listed here.

Abstract

Levodopa-induced dyskinesias (LIDs) are the most common and disabling adverse motor effect of therapy in Parkinson's disease (PD) patients. In this study, we investigated serotonergic mechanisms in LIDs development in PD patients using 11C-DASB PET to evaluate serotonin terminal function and 11C-raclopride PET to evaluate dopamine release. PD patients with LIDs showed relative preservation of serotonergic terminals throughout their disease. Identical levodopa doses induced markedly higher striatal synaptic dopamine concentrations in PD patients with LIDs compared with PD patients with stable responses to levodopa. Oral administration of the serotonin receptor type 1A agonist buspirone prior to levodopa reduced levodopa-evoked striatal synaptic dopamine increases and attenuated LIDs. PD patients with LIDs that exhibited greater decreases in synaptic dopamine after buspirone pretreatment had higher levels of serotonergic terminal functional integrity. Buspirone-associated modulation of dopamine levels was greater in PD patients with mild LIDs compared with those with more severe LIDs. These findings indicate that striatal serotonergic terminals contribute to LIDs pathophysiology via aberrant processing of exogenous levodopa and release of dopamine as false neurotransmitter in the denervated striatum of PD patients with LIDs. Our results also support the development of selective serotonin receptor type 1A agonists for use as antidyskinetic agents in PD.

Citing Articles

The effects of chemogenetic targeting of serotonin-projecting pathways on L-DOPA-induced dyskinesia and psychosis in a bilateral rat model of Parkinson's disease.

Lipari N, Galfano A, Venkatesh S, Grezenko H, Sandoval I, Manfredsson F Front Neural Circuits. 2024; 18:1463941.

PMID: 39634948 PMC: 11615880. DOI: 10.3389/fncir.2024.1463941.

Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.

Majumdar M, Badwaik H Curr Drug Targets. 2024; 25(15):987-1011.

PMID: 39313872 DOI: 10.2174/0113894501312703240826070530.

Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.

Chen Y, Kuo T, Wang V, Cheng P, Yi-Kung Huang E, Ma K J Parkinsons Dis. 2024; 14(5):941-964.

PMID: 38905058 PMC: 11307072. DOI: 10.3233/JPD-240080.

The chronic use of serotonin norepinephrine reuptake inhibitors facilitates dyskinesia priming in early Parkinson's disease.

Marano M, Pilotto A, Padovani A, Gupta D, Vivacqua G, Magliozzi A J Neurol. 2024; 271(7):3711-3720.

PMID: 38720139 DOI: 10.1007/s00415-024-12400-6.

Serotonin as a biomarker of toxin-induced Parkinsonism.

Buchanan A, Mena S, Choukari I, Vasa A, Crawford J, Fadel J Mol Med. 2024; 30(1):33.

PMID: 38429661 PMC: 10908133. DOI: 10.1186/s10020-023-00773-9.

References

Khan N, Valente E, Bentivoglio A, Wood N, Albanese A, Brooks D . Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol. 2002; 52(6):849-53. DOI: 10.1002/ana.10417. View

Saldana S, Barker E . Temperature and 3,4-methylenedioxymethamphetamine alter human serotonin transporter-mediated dopamine uptake. Neurosci Lett. 2004; 354(3):209-12. DOI: 10.1016/j.neulet.2003.10.032. View

Turkheimer F, Smith C, Schmidt K . Estimation of the number of "true" null hypotheses in multivariate analysis of neuroimaging data. Neuroimage. 2001; 13(5):920-30. DOI: 10.1006/nimg.2001.0764. View

Politis M . Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?. BMC Med. 2010; 8:80. PMC: 3003184. DOI: 10.1186/1741-7015-8-80. View

Munoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T . Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain. 2008; 131(Pt 12):3380-94. DOI: 10.1093/brain/awn235. View

Lamberg T, Kivisto K, Neuvonen P . Concentrations and effects of buspirone are considerably reduced by rifampicin. Br J Clin Pharmacol. 1998; 45(4):381-5. PMC: 1873961. DOI: 10.1046/j.1365-2125.1998.t01-1-00698.x. View

Rylander D, Parent M, OSullivan S, Dovero S, Lees A, Bezard E . Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol. 2010; 68(5):619-28. DOI: 10.1002/ana.22097. View

Maeda T, Nagata K, Yoshida Y, Kannari K . Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res. 2005; 1046(1-2):230-3. DOI: 10.1016/j.brainres.2005.04.019. View

Lees A, Shaw K, STERN G . "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease. Lancet. 1977; 2(8046):1034. DOI: 10.1016/s0140-6736(77)92939-7. View

10.

de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu J, Calne D . Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain. 2004; 127(Pt 12):2747-54. DOI: 10.1093/brain/awh290. View

11.

Rainero I, Gilli M, De Gennaro T, Chiado I, Delsedime M, Riccio A . Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients. Ital J Neurol Sci. 1988; 9(3):255-9. DOI: 10.1007/BF02334049. View

12.

Kannari K, Shen H, Arai A, Tomiyama M, Baba M . Reuptake of L-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci Lett. 2006; 402(1-2):62-5. DOI: 10.1016/j.neulet.2006.03.059. View

13.

Goetz C, Damier P, Hicking C, Laska E, Muller T, Olanow C . Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2006; 22(2):179-86. DOI: 10.1002/mds.21226. View

14.

Carta M, Carlsson T, Kirik D, Bjorklund A . Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007; 130(Pt 7):1819-33. DOI: 10.1093/brain/awm082. View

15.

Bara-Jimenez W, Bibbiani F, Morris M, Dimitrova T, Sherzai A, Mouradian M . Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord. 2005; 20(8):932-6. DOI: 10.1002/mds.20370. View

16.

Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M . Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport. 1999; 10(3):631-4. DOI: 10.1097/00001756-199902250-00034. View

17.

Ng K, Chase T, Colburn R, Kopin I . L-Dopa-induced release of cerebral monoamines. Science. 1970; 170(3953):76-7. DOI: 10.1126/science.170.3953.76. View

18.

Politis M, Oertel W, Wu K, Quinn N, Pogarell O, Brooks D . Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord. 2011; 26(11):1997-2003. DOI: 10.1002/mds.23743. View

19.

Kish S, Furukawa Y, Chang L, Tong J, Ginovart N, Wilson A . Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?. Nucl Med Biol. 2005; 32(2):123-8. DOI: 10.1016/j.nucmedbio.2004.10.001. View

20.

Logan J, Fowler J, Volkow N, Wang G, Ding Y, Alexoff D . Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996; 16(5):834-40. DOI: 10.1097/00004647-199609000-00008. View